Rationale for the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines
- DOI
- 10.1161/hypertensionaha.124.22821
- Published
- 2024-05
- Container
- Hypertension
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1161/hypertensionaha.124.22821,
title = {Rationale for the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines},
author = {Giuseppe Mancia and Mattias Brunström and Michel Burnier and Guido Grassi and Andrzej Januszewicz and Sverre E. Kjeldsen and Maria Lorenza Muiesan and Costas Thomopoulos and Konstantinos Tsioufis and Reinhold Kreutz},
year = {2024},
journal = {Hypertension},
doi = {10.1161/hypertensionaha.124.22821},
url = {https://doi.org/10.1161/hypertensionaha.124.22821}
}RIS
TY - JOUR TI - Rationale for the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines AU - Giuseppe Mancia AU - Mattias Brunström AU - Michel Burnier AU - Guido Grassi AU - Andrzej Januszewicz AU - Sverre E. Kjeldsen AU - Maria Lorenza Muiesan AU - Costas Thomopoulos AU - Konstantinos Tsioufis AU - Reinhold Kreutz PY - 2024 JO - Hypertension DO - 10.1161/hypertensionaha.124.22821 UR - https://doi.org/10.1161/hypertensionaha.124.22821 ER -
APA
Mancia, G., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Kjeldsen, S. E., Muiesan, M. L., Thomopoulos, C., Tsioufis, K., & Kreutz, R. (2024). Rationale for the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines. Hypertension. https://doi.org/10.1161/hypertensionaha.124.22821
Source records
- crossref · retrieved 2026-11-10T20:08:37.982Z